ValuEngine cut shares of Sarepta Therapeutics (NASDAQ:SRPT) from a strong-buy rating to a buy rating in a report issued on Wednesday morning, ValuEngine reports.

Several other brokerages have also recently issued reports on SRPT. Zacks Investment Research raised Sarepta Therapeutics from a sell rating to a hold rating in a report on Wednesday, March 13th. BidaskClub cut Sarepta Therapeutics from a hold rating to a sell rating in a report on Friday, March 22nd. Evercore ISI started coverage on Sarepta Therapeutics in a report on Thursday, April 11th. They issued an outperform rating and a $175.00 target price on the stock. BTIG Research set a $190.00 target price on Sarepta Therapeutics and gave the stock a buy rating in a report on Wednesday, April 17th. Finally, Piper Jaffray Companies lifted their target price on Sarepta Therapeutics from $200.00 to $208.00 and gave the stock an overweight rating in a report on Thursday, March 28th. Twenty-two research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of Buy and a consensus price target of $200.28.

NASDAQ:SRPT opened at $129.88 on Wednesday. The company has a quick ratio of 11.15, a current ratio of 12.17 and a debt-to-equity ratio of 0.35. Sarepta Therapeutics has a 52 week low of $95.21 and a 52 week high of $165.87.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($1.07) EPS for the quarter, beating the Zacks’ consensus estimate of ($2.05) by $0.98. The business had revenue of $87.01 million for the quarter, compared to analysts’ expectations of $86.92 million. Sarepta Therapeutics had a negative return on equity of 36.26% and a negative net margin of 124.66%. Equities research analysts expect that Sarepta Therapeutics will post -4.36 earnings per share for the current fiscal year.

In related news, Director Hans Lennart Rudolf Wigzell sold 10,000 shares of Sarepta Therapeutics stock in a transaction dated Thursday, May 23rd. The stock was sold at an average price of $120.00, for a total value of $1,200,000.00. Following the completion of the transaction, the director now owns 21,717 shares in the company, valued at $2,606,040. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 6.60% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC grew its position in Sarepta Therapeutics by 6.9% in the fourth quarter. FMR LLC now owns 10,565,177 shares of the biotechnology company’s stock worth $1,152,977,000 after acquiring an additional 677,947 shares in the last quarter. Vanguard Group Inc grew its position in Sarepta Therapeutics by 3.3% in the third quarter. Vanguard Group Inc now owns 5,384,899 shares of the biotechnology company’s stock worth $869,715,000 after acquiring an additional 170,999 shares in the last quarter. BlackRock Inc. grew its position in Sarepta Therapeutics by 0.8% in the fourth quarter. BlackRock Inc. now owns 4,845,231 shares of the biotechnology company’s stock worth $528,758,000 after acquiring an additional 36,972 shares in the last quarter. Janus Henderson Group PLC grew its position in Sarepta Therapeutics by 44.9% in the first quarter. Janus Henderson Group PLC now owns 2,666,043 shares of the biotechnology company’s stock worth $317,766,000 after acquiring an additional 826,449 shares in the last quarter. Finally, venBio Select Advisor LLC grew its position in Sarepta Therapeutics by 35.1% in the fourth quarter. venBio Select Advisor LLC now owns 1,275,000 shares of the biotechnology company’s stock worth $139,141,000 after acquiring an additional 331,500 shares in the last quarter.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.

See Also: Short Selling Stocks, A Beginner’s Guide

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.